Scholarlink

Purpose <p>Overall survival after transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) is heterogeneous, and portal venous remodeling may contribute to outcome variability. We evaluated whether portal venous local vessel volume fraction (LVVF) maps carry prognostic information for 2-year overall survival (OS) after TACE, with a prespecified focus on the intermediate-stage Barcelona Clinic Liver Cancer (BCLC)-B subgroup.</p> Methods <p>In this retrospective study, pre-TACE portal venous CT from 105 patients in the public HCC-TACE–Seg dataset were analyzed. OS was dichotomized at 104 weeks (OS &lt; 104 weeks vs. OS ≥ 104 weeks). LVVF maps were computed by convolving the portal venous vessel mask with a 2-mm-radius 3D spherical kernel to yield voxel-wise local vessel volume fractions. In the full cohort, image-based risk models were trained and evaluated with fixed five-fold patient-level cross-validation using CT-only, LVVF-only, and combined CT+LVVF inputs. In the prespecified BCLC-B subgroup, incremental prognostic value of LVVF was assessed primarily via model ablation (CT-only vs. CT+LVVF) under a matched cross-validation protocol.</p> Results <p>LVVF-only modeling achieved a cross-validated area under the receiver operating characteristic curve (AUC) of 0.76 ± 0.03 with recall 0.94 ± 0.05. In the BCLC-B subgroup (<i>n</i> = 24; 13 events), incorporating LVVF improved risk stratification compared with CT-only [CT-only AUC/F1, 0.77/0.69 (95% CI for AUC, 0.67–0.80); LVVF-only F1, 0.85; CT+LVVF AUC/F1, 0.91/0.86 (95% CI for AUC, 0.80–1.00)]; high-risk recall increased from 0.75 (CT-only) to 1.00 (LVVF-only) and 0.95 (CT+LVVF).</p> Conclusion <p>Portal venous LVVF maps carried prognostic information for 2-year OS after TACE, supporting LVVF maps as a potential vessel-aware imaging biomarker. In the prespecified BCLC-B subgroup, incorporating LVVF improved risk stratification compared with CT-only, particularly for identifying high-risk patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Vessel-density distribution mapping on portal venous CT and deep learning for 2-year overall survival risk stratification after transarterial chemoembolization in hepatocellular carcinoma

  • 期刊论文

  • 发表日期：

    2026年4月7日

查看全文
  • Chen Wang,
  • Yimeng He,
  • Yufeng Wang,
  • Zengtian Deng,
  • Lixia Wang,
  • Debiao Li

摘要

Purpose

Overall survival after transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) is heterogeneous, and portal venous remodeling may contribute to outcome variability. We evaluated whether portal venous local vessel volume fraction (LVVF) maps carry prognostic information for 2-year overall survival (OS) after TACE, with a prespecified focus on the intermediate-stage Barcelona Clinic Liver Cancer (BCLC)-B subgroup.

Methods

In this retrospective study, pre-TACE portal venous CT from 105 patients in the public HCC-TACE–Seg dataset were analyzed. OS was dichotomized at 104 weeks (OS < 104 weeks vs. OS ≥ 104 weeks). LVVF maps were computed by convolving the portal venous vessel mask with a 2-mm-radius 3D spherical kernel to yield voxel-wise local vessel volume fractions. In the full cohort, image-based risk models were trained and evaluated with fixed five-fold patient-level cross-validation using CT-only, LVVF-only, and combined CT+LVVF inputs. In the prespecified BCLC-B subgroup, incremental prognostic value of LVVF was assessed primarily via model ablation (CT-only vs. CT+LVVF) under a matched cross-validation protocol.

Results

LVVF-only modeling achieved a cross-validated area under the receiver operating characteristic curve (AUC) of 0.76 ± 0.03 with recall 0.94 ± 0.05. In the BCLC-B subgroup (n = 24; 13 events), incorporating LVVF improved risk stratification compared with CT-only [CT-only AUC/F1, 0.77/0.69 (95% CI for AUC, 0.67–0.80); LVVF-only F1, 0.85; CT+LVVF AUC/F1, 0.91/0.86 (95% CI for AUC, 0.80–1.00)]; high-risk recall increased from 0.75 (CT-only) to 1.00 (LVVF-only) and 0.95 (CT+LVVF).

Conclusion

Portal venous LVVF maps carried prognostic information for 2-year OS after TACE, supporting LVVF maps as a potential vessel-aware imaging biomarker. In the prespecified BCLC-B subgroup, incorporating LVVF improved risk stratification compared with CT-only, particularly for identifying high-risk patients.